Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have earned a consensus rating of “Buy” from the eight research firms that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $7.67.

TRVI has been the subject of several research reports. Raymond James assumed coverage on Trevi Therapeutics in a research note on Friday, August 30th. They issued an “outperform” rating and a $9.00 target price for the company. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Leerink Partners initiated coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price on the stock. HC Wainwright began coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They set a “buy” rating and a $6.00 price target for the company. Finally, Leerink Partnrs raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the transaction, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the sale, the insider now owns 220,315 shares of the company’s stock, valued at $608,069.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at $644,205.26. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,355 shares of company stock valued at $116,663. Corporate insiders own 24.37% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD bought a new stake in Trevi Therapeutics in the 1st quarter valued at approximately $47,000. Hsbc Holdings PLC bought a new stake in shares of Trevi Therapeutics in the second quarter worth $61,000. The Manufacturers Life Insurance Company boosted its holdings in Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after purchasing an additional 11,450 shares during the last quarter. American Century Companies Inc. grew its position in Trevi Therapeutics by 17.1% in the second quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after purchasing an additional 7,902 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in Trevi Therapeutics in the 1st quarter valued at $208,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Stock Performance

Shares of TRVI stock opened at $3.33 on Tuesday. The stock’s fifty day moving average is $3.03 and its 200-day moving average is $2.92. Trevi Therapeutics has a 52 week low of $0.97 and a 52 week high of $4.00. The stock has a market capitalization of $234.55 million, a PE ratio of -9.79 and a beta of 0.96.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter in the previous year, the business posted ($0.07) EPS. As a group, analysts forecast that Trevi Therapeutics will post -0.47 earnings per share for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.